SCHEMBL6668062

SCHEMBL6668062

COc1c(N2CC3CCCNC3C2)c(F)cc2c(=O)[nH]c(=O)n(C3CC3)c12

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.61
HPGD P15428 4/20 0.61
ALDH1A1 P00352 3/20 0.61
HSD17B10 Q99714 2/20 0.61
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61
KCNH2 Q12809 3/20 0.41
POLB P06746 1/20 0.41
PRKD3 O94806 1/20 0.41
ALOX15 P16050 1/20 0.41
OPRM1 P35372 1/20 0.41
CLK2 P49760 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HRH4 Q9H3N8 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6674258 0.88 KDM4E (0.49) KDM4EHPGDALDH1A1HSD17B10MEN1
SCHEMBL1384360 0.84 KDM4E (0.59) KDM4EHPGDALDH1A1HSD17B10MEN1
SCHEMBL6667968 0.83 KDM4E (0.42) KDM4EHPGDALDH1A1HSD17B10MEN1
SCHEMBL29836972 0.82 KDM4E (0.67) KDM4EHPGDALDH1A1HSD17B10MEN1
SCHEMBL608933 0.82 KDM4E (0.60) KDM4EHPGDALDH1A1HSD17B10MEN1
SCHEMBL2934909 0.82 KDM4E (0.60) KDM4EHPGDALDH1A1HSD17B10MEN1
Hydrochloric Acid SCHEMBL606301 0.81 KDM4E (0.61) KDM4EHPGDALDH1A1HSD17B10MEN1
Hydrochloric Acid SCHEMBL607001 0.81 KDM4E (0.61) KDM4EHPGDALDH1A1HSD17B10MEN1
SCHEMBL30902552 0.80 KDM4E (0.68) KDM4EHPGDALDH1A1HSD17B10MEN1
SCHEMBL28923970 0.80 KDM4E (0.68) KDM4EHPGDALDH1A1HSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401830-A2 QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS Warner-Lambert Company LLC (US) 2004-03-31 EP claimed
US-20030114666-A1 Having quinazolindione core structure; non-antibiotic resistance WARNER-LAMBERT COMPANY 2003-06-19 US claimed
WO-2002102793-A2 QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY LLC (US) 2002-12-27 WO claimed
US-20030114666-A1 Having quinazolindione core structure; non-antibiotic resistance WARNER-LAMBERT COMPANY 2003-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114666-A1 Having quinazolindione core structure; non-antibiotic resistance ABCC1, RPS6KA1, SIGMAR1 KDM4E 1886/4885HPGD 633/4885ALDH1A1 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.